drugset
drugset / Trial / NCT02670070

BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone

NCT02670070 ↗

Phase 1 Unknown 37 enrolled LG Life Sciences
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.

Timeline

Start
2016-03
Primary completion
2016-04
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg —
Subject Rosuvastatin Small molecule 20 mg —

Indications

No indication recorded.